Autoimmune mechanisms are implicated in both myasthenia gravis (MG) and multiple sclerosis (MS), and hypothesis of a common immunological mechanism of pathogenesis is supported by the fact that this rare combination of the two diseases occurs more frequently than expected by random association. Although MS is primarily mediated by T lymphocytes and MG primarily involves the destruction of the neuromuscular junction by antibodies, there are evidences that support both cell-mediated and humoral immunity are involved in the pathogenesis of both diseases. Different studies have shown dysfunction of T cells as well as B cells involved in the pathogenesis of both disorders. Previous case reports, mainly present female patients who had a mild presentation of MG, either prior or after diagnosis of MS. In this article, in addition to presenting a unique male patient with a previous diagnosis of MS, who presented with MG crisis, we aimed to review the literature to find the common immunological mechanisms involved in the pathogenesis of MG and MS.
COVID-19 (Coronavirus disease 2019) caused by SARS-CoV-2 has a diverse constellation of neurological manifestations that include encephalopathy, stroke, Guillain–Barré syndrome, myelitis, and encephalitis. Intraluminal carotid thrombi (ILT) are infrequent lesions seen in only 1.6% of patients with acute ischemic stroke. Underlying atherosclerosis is the most common lesion associated with ILT formation. However, with COVID-19, we have encountered ILT in patients without significant atherosclerotic disease. The endothelial inflammation and hypercoagulable state associated with COVID-19 pose a risk of arterial and venous thromboembolism and could have contributed to this presentation although the exact pathophysiology and optimal treatment of ILT in COVID-19 remain elusive. Herein, we present a series of ischemic stroke patients with carotid ILT in the setting of a recent SARS-CoV-2 infection.
Background: Intraluminal carotid thrombi (ILT) are uncommon and present in only 0.4 to 1.5 % of patients with stroke. The endothelial inflammation and hypercoagulable state associated with COVID-19 (caused by SARS-CoV-2) poses a risk of arterial and venous thromboembolism. Herein, we present a series of stroke patients with ILT in the setting of a recent SARS-CoV-2 infection. Methods and Results: From July 9th, 2020 to August 17th, 2020, four patients were identified with acute ischemic stroke with varying thrombus burden but similar morphological patterns of ILT. All patients had evidence of recent SARS-CoV-2 infection as confirmed by PCR (n=3) or IgG antibody (n=1) in addition to clinical and radiological manifestations consistent with COVID-19. General characteristics and imaging of the patients are shown in table 1. Mean age was 55.3 ±7.7 years. Most patients (3) had at least two vascular risk factors and none had a central embolic source other than ILT. D-Dimer was profoundly elevated in 3 patients. ILT involved the cervical (3) and intracranial (1) internal carotid artery. COVID-19 symptoms ranged from mild transient respiratory symptoms to severe pneumonia requiring critical care support. None of the patients received acute reperfusion therapy either due to presentation beyond the therapeutic window or due to the absence of large vessel occlusion and/or unfavorable imaging profile. Conclusion: In this small case series of relatively young patients with acute ischemic stroke we found an association between COVID-19 infection and ILT. This suggests a distinctive pathophysiological pattern of stroke in COVID-19 patients. Further studies are necessary to elucidate the underlying pathophysiology and target specific treatment modalities. Download figure